Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Roos S G SablerollesWim J R RietdijkAbraham GoorhuisDouwe F PostmaLeo G VisserDaryl GeersKatharina S SchmitzHannah M Garcia GarridoMarion P G KoopmansVirgil A S H DalmNeeltje A KootstraAnke L W HuckriedeMelvin LafeberDebbie van BaarleCorine H GeurtsvanKesselRory D de VriesPaul-Hugo M van der Kuynull nullPublished in: The New England journal of medicine (2022)
The Ad26.COV2.S and mRNA boosters had an acceptable safety profile and were immunogenic in health care workers who had received a priming dose of Ad26.COV2.S vaccine. The strongest responses occurred after boosting with mRNA-based vaccines. Boosting with any available vaccine was better than not boosting. (Funded by the Netherlands Organization for Health Research and Development ZonMw; SWITCH ClinicalTrials.gov number, NCT04927936.).